PMID- 37994080
OWN - NLM
STAT- Publisher
LR  - 20231123
IS  - 1592-8721 (Electronic)
IS  - 0390-6078 (Linking)
DP  - 2023 Nov 23
TI  - t(11;14) status is stable between diagnosis and relapse, and concordant between 
      detection methodologies based on fluorescence in situ hybridization and 
      next-generation sequencing in patients with multiple myeloma.
LID - 10.3324/haematol.2023.284072 [doi]
AB  - Multiple myeloma (MM) is associated with a wide variety of recurrent genomic 
      alterations. The most common translocation in MM is t(11;14). In this 
      retrospective, single-center, non-interventional study, patient bone marrow 
      samples were examined at diagnosis and at relapse(s) following treatment with 
      anti-myeloma regimens to determine whether t(11;14) status was stable over time. 
      This Stability Cohort consisted of 272 patients, of whom 118 were 
      t(11;14)-positive at diagnosis and 154 were negative. All patients in the 
      Stability Cohort retained the same t(11;14) status at relapse that they had at 
      diagnosis of MM. Sixteen patients who had t(11;14)-positive MM at diagnosis had 
      multiple longitudinal FISH assessments at relapse events, which remained 
      t(11;14)-positive across all time points. Patients who had t(11;14)-positive 
      disease at diagnosis of monoclonal gammopathy of unknown significance (MGUS) or 
      smoldering multiple myeloma (SMM) also retained t(11;14) positivity through MM 
      diagnosis and relapse. The t(11;14) fusion patterns also remained constant for 
      90% of patients. For detection of t(11;14), results from fluorescence in situ 
      hybridization (FISH) and next generation sequencing (NGS) were compared to 
      determine the rate of concordance between these 2 methods. This Concordance 
      Cohort contained 130 patients, of whom 66 had t(11;14)-positive disease and 64 
      were t(11;14)-negative. In this sample set, the concordance between FISH and 
      NGS-based detection of t(11;14) was 100%. These results strongly suggest that the 
      t(11;14) rearrangement remains stable during the full disease course in patients 
      with multiple myeloma and can be detected by FISH- and NGS-based methodologies.
FAU - Avet-Loiseau, Herve
AU  - Avet-Loiseau H
AD  - Unite de Genomique du Myelome, Institut Universitaire du Cancer 
      Toulouse-Oncopole, Toulouse.
FAU - Thiebaut-Millot, Raphaele
AU  - Thiebaut-Millot R
AD  - AbbVie, Inc., North Chicago, IL.
FAU - Li, Xiaotong
AU  - Li X
AD  - AbbVie, Inc., North Chicago, IL.
FAU - Ross, Jeremy A
AU  - Ross JA
AD  - AbbVie, Inc., North Chicago, IL.
FAU - Hader, Carlos
AU  - Hader C
AD  - AbbVie, Inc., North Chicago, IL. carlos.hader@abbvie.com.
LA  - eng
PT  - Journal Article
DEP - 20231123
PL  - Italy
TA  - Haematologica
JT  - Haematologica
JID - 0417435
SB  - IM
EDAT- 2023/11/23 06:42
MHDA- 2023/11/23 06:42
CRDT- 2023/11/23 03:46
PHST- 2023/08/14 00:00 [received]
PHST- 2023/11/23 06:42 [medline]
PHST- 2023/11/23 06:42 [pubmed]
PHST- 2023/11/23 03:46 [entrez]
AID - 10.3324/haematol.2023.284072 [doi]
PST - aheadofprint
SO  - Haematologica. 2023 Nov 23. doi: 10.3324/haematol.2023.284072.